BACKGROUND: The Take Control of Your Blood Pressure trial evaluated the effect of a multicomponent telephonic behavioral lifestyle intervention, patient self-monitoring, and both interventions combined compared with usual care on reducing systolic blood pressure during 24 months. The combined intervention led to a significant reduction in systolic blood pressure compared with usual care alone. We examined direct and patient time costs associated with each intervention. METHODS: We conducted a prospective economic evaluation alongside a randomized controlled trial of 636 patients with hypertension participating in the study interventions. Medical costs were estimated using electronic data representing medical services delivered within the health system. Intervention-related costs were derived using information collected during the trial, administrative records, and published unit costs. RESULTS: During 24 months, patients incurred a mean of $6,965 (s.d., $22,054) in inpatient costs and $8,676 (s.d., $9,368) in outpatient costs, with no significant differences among the intervention groups. With base-case assumptions, intervention costs were estimated at $90 (s.d., $2) for home blood pressure monitoring, $345 (s.d., $64) for the behavioral intervention ($31 per telephone encounter), and $416 (s.d., $93) for the combined intervention. Patient time costs were estimated at $585 (s.d., $487) for home monitoring, $55 (s.d., $16) for the behavioral intervention, and $741 (s.d., $529) for the combined intervention. CONCLUSIONS: Our analysis demonstrated that the interventions are cost-additive to the health-care system in the short term and that patients' time costs are nontrivial.
BACKGROUND: The Take Control of Your Blood Pressure trial evaluated the effect of a multicomponent telephonic behavioral lifestyle intervention, patient self-monitoring, and both interventions combined compared with usual care on reducing systolic blood pressure during 24 months. The combined intervention led to a significant reduction in systolic blood pressure compared with usual care alone. We examined direct and patient time costs associated with each intervention. METHODS: We conducted a prospective economic evaluation alongside a randomized controlled trial of 636 patients with hypertension participating in the study interventions. Medical costs were estimated using electronic data representing medical services delivered within the health system. Intervention-related costs were derived using information collected during the trial, administrative records, and published unit costs. RESULTS: During 24 months, patients incurred a mean of $6,965 (s.d., $22,054) in inpatient costs and $8,676 (s.d., $9,368) in outpatient costs, with no significant differences among the intervention groups. With base-case assumptions, intervention costs were estimated at $90 (s.d., $2) for home blood pressure monitoring, $345 (s.d., $64) for the behavioral intervention ($31 per telephone encounter), and $416 (s.d., $93) for the combined intervention. Patient time costs were estimated at $585 (s.d., $487) for home monitoring, $55 (s.d., $16) for the behavioral intervention, and $741 (s.d., $529) for the combined intervention. CONCLUSIONS: Our analysis demonstrated that the interventions are cost-additive to the health-care system in the short term and that patients' time costs are nontrivial.
Authors: Judith E Bosmans; Oscar H Brook; Hein P J van Hout; Martine C de Bruijne; Hugo Nieuwenhuyse; Lex M Bouter; Wim A B Stalman; Maurits W van Tulder Journal: Pharmacoeconomics Date: 2007 Impact factor: 4.981
Authors: Andrew J Palmer; Sean Dinneen; James R Gavin; Alastair Gray; William H Herman; Andrew J Karter Journal: Curr Med Res Opin Date: 2006-05 Impact factor: 2.580
Authors: Bruce M Psaty; Thomas Lumley; Curt D Furberg; Gina Schellenbaum; Marco Pahor; Michael H Alderman; Noel S Weiss Journal: JAMA Date: 2003-05-21 Impact factor: 56.272
Authors: Thomas G Pickering; Nancy Houston Miller; Gbenga Ogedegbe; Lawrence R Krakoff; Nancy T Artinian; David Goff Journal: Hypertension Date: 2008-05-22 Impact factor: 10.190
Authors: Shelby D Reed; Yanhong Li; Shital Kamble; Daniel Polsky; Felicia L Graham; Margaret T Bowers; Gregory P Samsa; Sara Paul; Kevin A Schulman; David J Whellan; Barbara J Riegel Journal: Circ Cardiovasc Qual Outcomes Date: 2011-12-06
Authors: Verughese Jacob; Sajal K Chattopadhyay; Anilkrishna B Thota; Krista K Proia; Gibril Njie; David P Hopkins; Ramona K C Finnie; Nicolaas P Pronk; Thomas E Kottke Journal: Am J Prev Med Date: 2015-11 Impact factor: 5.043
Authors: Linnea A Polgreen; Barry L Carter; Philip M Polgreen; Peter M Snyder; Daniel K Sewell; Emine O Bayman; Shelby L Francis; Jacob E Simmering; Christopher Parker; Rachel Finkelstein Journal: Contemp Clin Trials Date: 2020-10-07 Impact factor: 2.226
Authors: Verughese Jacob; Sajal K Chattopadhyay; Krista K Proia; David P Hopkins; Jeffrey Reynolds; Anilkrishna B Thota; Christopher D Jones; Daniel T Lackland; Kimberly J Rask; Nicolaas P Pronk; John M Clymer; Ron Z Goetzel Journal: Am J Prev Med Date: 2017-08-14 Impact factor: 5.043
Authors: Rebecca A Shelby; Caroline S Dorfman; Hayden B Bosworth; Francis Keefe; Linda Sutton; Lynda Owen; Leonor Corsino; Alaattin Erkanli; Shelby D Reed; Sarah S Arthur; Tamara Somers; Nadine Barrett; Scott Huettel; Juan Marcos Gonzalez; Gretchen Kimmick Journal: Contemp Clin Trials Date: 2018-11-22 Impact factor: 2.226